Txtm.Pk
TXTM.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
Business. TXTM.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TXTM.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
TXTM.PK exhibits a severely negative capital structure, with total liabilities of $5.7 billion and total equity of -$5.7 billion, resulting in a debt-to-equity ratio of -0.25. The company's liquidity is further strained by a current ratio of 0.0, indicating no short-term liquidity buffer. Operating cash flow is negative at -$365.66 million, and the company has a long-term debt of $1.43 billion.
Profitability metrics are highly negative, with a return on assets of -318.804% and a return on equity of 25.4%. These figures indicate that the company is generating substantial losses relative to its asset base and equity, which is atypical for the biotechnology and medical research industry.
TXTM.PK's revenue concentration is not disclosed in the available data, but the company's financial snapshot suggests a lack of diversification in revenue sources, given the absence of segment-specific revenue breakdowns. The company's operating income is -$927.31 million, and net income is -$1.45 billion, indicating a lack of profitability across its operations.
The company's growth trajectory is not clearly defined in the available data, but the significant negative operating and net income figures suggest a lack of growth in the current fiscal year. The company's revenue of $640 million is relatively low compared to its liabilities and losses, indicating a need for substantial revenue growth to improve its financial position.
Risk factors for TXTM.PK include high liquidity risk due to a current ratio of 0.0 and a negative operating cash flow of -$365.66 million. The company's dilution potential is low, but the negative equity position and high debt levels suggest a need for careful monitoring of capital structure changes. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's financial position is highly leveraged.
Recent events for TXTM.PK are not detailed in the available data, but the company's financial snapshot suggests a need for significant operational and financial improvements to address its current losses and liquidity issues.
- TXTM.PK has a severely negative capital structure with total liabilities of $5.7 billion and total equity of -$5.7 billion.
- The company's liquidity is critically low, with a current ratio of 0.0 and a negative operating cash flow of -$365.66 million.
- Profitability metrics are highly negative, with a return on assets of -318.804% and a return on equity of 25.4%.
- The company's financial position is highly leveraged, with a long-term debt of $1.43 billion and a debt-to-equity ratio of -0.25.
- TXTM.PK's revenue of $640 million is relatively low compared to its liabilities and losses, indicating a need for substantial revenue growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- TXTM.PK Market data — financials · 2026-05-29